Free Trial

Abingdon Health (ABDX) Competitors

Abingdon Health logo
GBX 6.36 -0.14 (-2.15%)
As of 12:36 PM Eastern

ABDX vs. AGL, YGEN, PRM, GDR, VRCI, GENI, DMTR, LLAI, LLA, and IDHC

Should you be buying Abingdon Health stock or one of its competitors? The main competitors of Abingdon Health include ANGLE (AGL), Yourgene Health (YGEN), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), LLA.L,0P0001T9GN,0 (LLA), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.

Abingdon Health vs.

ANGLE (LON:AGL) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.

ANGLE currently has a consensus target price of GBX 40, suggesting a potential upside of 300.00%. Given ANGLE's stronger consensus rating and higher probable upside, equities analysts plainly believe ANGLE is more favorable than Abingdon Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANGLE
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Abingdon Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.44M13.19-£21.76M-£6.76-1.48
Abingdon Health£3.84M3.20-£796.37K-£0.41-15.46

18.8% of ANGLE shares are owned by institutional investors. Comparatively, 33.5% of Abingdon Health shares are owned by institutional investors. 16.2% of ANGLE shares are owned by company insiders. Comparatively, 48.9% of Abingdon Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Abingdon Health has a net margin of -20.72% compared to ANGLE's net margin of -890.91%. Abingdon Health's return on equity of -62.56% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-890.91% -76.01% -29.89%
Abingdon Health -20.72%-62.56%-17.93%

In the previous week, Abingdon Health had 2 more articles in the media than ANGLE. MarketBeat recorded 3 mentions for Abingdon Health and 1 mentions for ANGLE. ANGLE's average media sentiment score of 0.48 beat Abingdon Health's score of -0.65 indicating that ANGLE is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ANGLE
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Abingdon Health
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

ANGLE has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Abingdon Health has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

ANGLE received 183 more outperform votes than Abingdon Health when rated by MarketBeat users.

CompanyUnderperformOutperform
ANGLEOutperform Votes
183
62.46%
Underperform Votes
110
37.54%
Abingdon HealthN/AN/A

Summary

Abingdon Health beats ANGLE on 9 of the 17 factors compared between the two stocks.

Remove Ads
Get Abingdon Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABDX vs. The Competition

MetricAbingdon HealthDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£12.32M£872.93M£5.63B£2.60B
Dividend YieldN/A5.44%4.57%4.82%
P/E Ratio-15.461.9423.33141.21
Price / Sales3.20336.31388.46281,678.09
Price / Cash2.2511.4238.1627.94
Price / Book8.742.886.894.61
Net Income-£796,369.64£308.37B£3.20B£5.78B
7 Day Performance-14.05%0.70%-3.02%1.37%
1 Month Performance-11.30%-9.22%1.63%7.22%
1 Year Performance-31.24%-6.85%9.74%108.14%

Abingdon Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABDX
Abingdon Health
N/AGBX 6.36
-2.2%
N/A-36.9%£12.32M£3.84M-15.4684Earnings Report
News Coverage
Gap Down
AGL
ANGLE
1.7137 of 5 stars
GBX 9.60
-1.5%
GBX 40
+316.7%
-16.0%£30.94M£2.44M-1.42650Gap Up
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
PRM
Proteome Sciences
N/AGBX 4.40
+8.4%
N/A+2.8%£12.99M£10.88B-3.18240Gap Up
GDR
genedrive
N/AGBX 1.79
-4.5%
N/A-52.3%£10.17M£1.50M-0.5043Earnings Report
VRCI
Verici Dx
N/AGBX 2.47
+9.8%
N/A-74.1%£7.50M£5.91M-1.4319Gap Up
High Trading Volume
GENI
GENinCode
N/AGBX 3.10
-1.6%
N/A-54.0%£5.50M£2.67M-0.902,300Gap Down
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLAI
LungLife AI
N/AGBX 1.10
-12.0%
N/A-96.4%£365,000.00£33,871.03-0.0915Gap Up
LLA
LLA.L,0P0001T9GN,0
N/AN/AN/AN/A£0.00N/A-8.3315Gap Down
High Trading Volume
IDHC
Integrated Diagnostics
N/AGBX 0.31
-0.9%
N/A-9.2%£9.24B£23.29T11.676,692
Remove Ads

Related Companies and Tools


This page (LON:ABDX) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners